NewAmsterdam Pharma Company N.V. Ordinary Shares Cash Flow-to-Debt Ratio
NewAmsterdam Pharma Company N.V. Ordinary Shares cash flow-to-debt ratio. NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) has a Cash Flow-to-Debt Ratio of -0.56x as of September 2025, meaning its operating cash flow of $-32.77 Million could theoretically repay -1% of its total liabilities ($58.36 Million) in one year. Check NewAmsterdam Pharma Company N.V. Ordinar (NAMS) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of NewAmsterdam Pharma Company N.V. Ordinary Shares (2020–2024)
Cash flow-to-debt ratio of NewAmsterdam Pharma Company N.V. Ordinary Shares from 2020 to 2024. Historical debt coverage capacity for NewAmsterdam Pharma Company N.V. Ordinary Shares across 5 annual periods. Check NAMS cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
NewAmsterdam Pharma Company N.V. Ordinary Shares Cash Flow-to-Debt Ratio by Year (2020–2024)
NewAmsterdam Pharma Company N.V. Ordinary Shares cash flow-to-debt ratio by year from 2020 to 2024. Year-by-year debt coverage analysis for NewAmsterdam Pharma Company N.V. Ordinary Shares. For the full cash flow conversion analysis, see NewAmsterdam Pharma Company N.V. Ordinar (NAMS) cash conversion ratio.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -1.48x | $-158.56 Million | $107.12 Million | ▲ +38.5% |
| 2023 | -2.41x | $-141.22 Million | $58.70 Million | ▼ -1192.4% |
| 2022 | 0.22x | $10.66 Million | $48.43 Million | ▲ +108.5% |
| 2021 | -2.60x | $-29.51 Million | $11.36 Million | ▼ -338.9% |
| 2020 | -0.59x | $-7.34 Million | $12.41 Million | — |